Docon Technologies, the promoter and subsidiary of digital healthcare platform API Holdings, has offloaded 9.9% equity stake in Thyrocare Technologies through multiple transactions on August 14. According to The Hindu BusinessLine, Docon sold 1,57,69,696 equity shares, representing 9.9% of paid-up equity, for ₹985.86 crore at a price range of ₹624-631.71 per share. The transaction involved 14 domestic and global institutional investors, with more than 1.31 crore shares sold through block deals and 10 lakh shares through bulk deals on NSE and 16.01 lakh shares through bulk deals on BSE. Following this sale, Docon's holding in the diagnostics chain dropped to 51.02% from 60.92%, continuing the promoter group's strategic divestment. This follows the earlier stake sale where promoters offloaded nearly 1.57 crore shares through a block deal, reducing Docon Technologies' holding from 60.92% to 51.02% of the total paid-up equity share capital.
HSBC Mutual Fund emerged as the biggest buyer, acquiring additional 29.99 lakh shares (1.88% stake) for ₹187.18 crore. As per The Hindu BusinessLine, the asset management company already held 3.84% stake in the company as of June 2026, making it a significant new investor. Kotak Mahindra Life Insurance Company picked up 24 lakh shares (1.5% stake) for ₹149.76 crore. Aditya Birla Sun Life AMC has bought 6.5 lakh shares for ₹40.56 crore, while ICICI Prudential MF acquired 8.01 lakh shares for ₹49.98 crore, which was in addition to their existing shareholdings of 3.15% and 5.57% respectively. Other notable buyers included DSP MF, WhiteOak Capital MF, ITI MF, Kotak Mahindra Life Insurance Company, Tata AIA Life Insurance, Morgan Stanley, Citigroup Global Markets, HBM Healthcare Investments (Cayman), and Kuwait Investment Authority through block deals on NSE. The latest transaction follows Docon's sale of a 10% stake in Thyrocare for ₹667 crore in October last year.
Thyrocare shares gained nearly 3% to ₹621.95 on NSE and over 2% to ₹622 on BSE following the promoter stake sale announcement. According to The Hindu BusinessLine, the stock gained nearly 3% to ₹621.95 on NSE and over 2% to ₹622 on BSE following the transaction, demonstrating positive investor sentiment despite the significant stake reduction. The immediate market reaction reflects investor confidence in the institutional participation and the company's strong fundamentals. The buying price range of ₹624-631.71 per share indicates the market's assessment of the company's valuation at that time, with the shares being sold across multiple exchanges through both bulk and block deals.
For the recently concluded June quarter (Q1) of fiscal year 2026-27, Thyrocare Technologies delivered impressive financial results. According to Business Standard, the company posted a 24.3% year-on-year growth in consolidated revenue to ₹240.02 crore for the first quarter of FY27. Revenue from operations saw a 24% year-on-year uptick to ₹240.02 crore, driven primarily by a 26% increase in the Pathology segment. The earnings before interest, tax, depreciation and amortisation (EBITDA) grew to ₹77.27 crore, up 34% year-on-year. The company processed 55.2 million tests in Q1FY27, marking a strong 28% year-on-year growth and making it the largest diagnostic test volume processor in India. The company also reported PAT increasing 34.1% YoY to ₹51.33 crore for the quarter.
Back in December last year, Thyrocare Technologies is positioning itself for its next phase of growth by expanding into new testing categories and tapping into rising demand for preventive health checks. One of the company's latest initiatives is its testing package linked to GLP-1 weight-loss drugs. As reported by CNBC TV18, Rahul Guha, MD and CEO of Thyrocare Technologies, said, "We were the first to launch the GLP-1, so Thyrocare is always known to be at the front runner. I definitely believe there is a huge opportunity." He said the package was launched only about three weeks ago and the company has not yet begun full-scale promotion. The company has also strengthened its specialty portfolio with the addition of allergy testing and entry into genomics through the launch of NIPT, with a phased expansion of the test menu underway.
Despite the recent market volatility, Thyrocare Technologies has demonstrated strong long-term performance. According to The Economic Times, Thyrocare shares have gained around 3% in a week and 20% in a month, being up more than 37% in 2026 so far. The stock has overall gained 34% in one year and has delivered stellar 221% returns over three years and 38% over five years. The company currently has a market capitalisation of around ₹9,797 crore. Nearly 69 lakh retail shareholders meanwhile held 8.6% stake in the company as of the end of the April-June quarter of the ongoing financial year 2027. The positive momentum occurred alongside the successful execution of the block deal, indicating investor confidence in the company's strategic initiatives and growth prospects.
